Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the United States (US) Food and Drug Administration (FDA) for its fusogen contained in the NTX-001 treatment kit. This designation marks a significant milestone in developing NTX-001, a novel treatment for peripheral nerve injury requiring repair.

Neuraptive Therapeutics, Inc., a leader in nerve repair and regeneration, is pleased to announce a significant milestone in transforming the treatment paradigm for peripheral nerve injuries. The successful demonstration of proof of concept in the NEUROFUSE study of NTX-001 marks an unprecedented advancement in providing hope for faster and more complete functional recovery to individuals impacted by peripheral nerve transections.